Clinical trial · Interventional
Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia
NCT04174586CI-TRIAL-00044267unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Discuss the effectiveness and safety of cord blood microtransplantation for treatment of acute myeloid leukemia
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Efficiency | — | UNRESOLVED | — |
| Safety Issues | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| microtransplantation | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- cord blood group
- description
- standard induction and consolidation chemotherapy with cord blood microtransplantation
- interventionNames
- Biological: microtransplantation
Primary outcomes (2)
- measure
- complete remission rate
- timeFrame
- 1 month
- description
- Bone marrow \<5% blasts； Absolute neutrophil count \>1000/mcL； Platelets ≥100,000/mcL；No residual evidence of extramedullary disease.
- measure
- time of hematopoietic recovery
- timeFrame
- 1 month
- description
- Absolute neutrophil count \>500/mcL; Platelets ≥20,000/mcL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. de novo acute myeloid leukemia 2. age 60-80 Exclusion Criteria: 1. have no suitable donor or donor refused 2. patient refused to accept donor cells
References
Publications (0)
Data not yet available
No reference posted for this study.